Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
about
A Review of Currently Available Fenofibrate and Fenofibric Acid FormulationsNanopharmaceuticals (part 1): products on the market.Has nanotechnology led to improved therapeutic outcomes?Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity.
P2860
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@en
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@nl
type
label
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@en
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@nl
prefLabel
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@en
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@nl
P2860
P356
P1433
P1476
Effectiveness of a fenofibrate ...... eart disease and dyslipidemia.
@en
P2093
Daniel Hilleman
Stephanie Maciejewski
P2860
P304
P356
10.1592/PHCO.28.5.570
P407
P577
2008-05-01T00:00:00Z